SEEGENE, INC. Logo

SEEGENE, INC.

Develops multiplex qPCR diagnostic assays and automated systems for labs and healthcare worldwide.

096530 | KO

Overview

Corporate Details

ISIN(s):
KR7096530001
LEI:
Country:
South Korea
Address:
서울특별시 송파구 오금로 91(방이동) 7층, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Seegene, Inc. is a global molecular diagnostics company specializing in the development and manufacturing of in vitro diagnostic (IVD) products. The company focuses on syndromic quantitative PCR (qPCR) technologies, offering multiplex assays that can simultaneously detect multiple pathogens from a single sample. Its product portfolio includes automated systems like STARlet-AIOS™ and solutions for respiratory infections, sexually transmitted infections (STIs), and HPV screening. Through strategic collaborations with partners such as Microsoft and a technology-sharing initiative called OneSystem™, Seegene aims to standardize and increase the accessibility of molecular diagnostics for healthcare providers and research laboratories worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-08 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 17.3 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 3.1 MB
2025-08-08 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.7 KB
2025-08-06 00:00
Notice of Dividend Amount
현금ㆍ현물배당결정 (분기배당)
Korean 8.4 KB
2025-08-06 00:00
Notice of Dividend Amount
중간(분기)배당을위한주주명부폐쇄(기준일)결정
Korean 5.3 KB
2025-08-06 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 31.3 KB
2025-08-01 00:00
Report Publication Announcement
결산실적공시예고
Korean 4.0 KB
2025-06-11 00:00
Transaction in Own Shares
[연장결정]주요사항보고서(자기주식취득신탁계약체결결정)
Korean 79.7 KB
2025-06-09 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 17.6 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 2.1 MB
2025-05-09 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.7 KB
2025-05-07 00:00
Notice of Dividend Amount
현금ㆍ현물배당결정 (분기배당)
Korean 8.4 KB
2025-05-07 00:00
Notice of Dividend Amount
중간(분기)배당을위한주주명부폐쇄(기준일)결정
Korean 5.3 KB
2025-05-07 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 31.4 KB
2025-05-02 00:00
Report Publication Announcement
결산실적공시예고
Korean 4.0 KB

Automate Your Workflow. Get a real-time feed of all SEEGENE, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SEEGENE, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SEEGENE, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA
LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB

Talk to a Data Expert

Have a question? We'll get back to you promptly.